Published Data in Metastatic Breast Cancer

SIR-Spheres® Y-90 resin microspheres have shown efficacy in the treatment of chemotherapy-refractory metastatic breast cancer (mBC) and in the treatment of liver progression during a treatment hiatus.

Overall, 86% of patients with chemotherapy-refractory liver metastases from breast cancer or with liver progression during a treatment hiatus after first- or second-line chemotherapy were alive 14 months after receiving SIR-Spheres Y-90 resin microspheres.1

Several other studies have reported on the efficacy of SIR-Spheres Y-90 resin microspheres in chemorefractory mBC.2-4 OS has ranged from 35 weeks to 13.6 months in these studies, which compares well with historical controls.

The use of SIR-Spheres Y-90 resin microspheres in chemorefractory mBC is further supported by a high proportion of patients with partial response (26–47%) or stable disease (39–63%).1-3

Reported complications across studies have generally been minor, with most adverse events being grade 1 or 2 that resolved without intervention.4 Overall, SIR-Spheres Y-90 resin microspheres are an effective and well-tolerated treatment option for unresectable liver metastases from breast cancer, which are often chemotherapy-refractory, or for the treatment of liver progression during a treatment hiatus.

1 Coldwell, DM et al. Int J Radiat Oncol Biol Phys 2007; 69: 800-804.
2 Haug AR et al. J Nucl Med 2012; 53: 371-377.
3 Saxena A et al. Ann Surg Oncol 2014; 21: 1296-1303.
4 Fendler WP et al. J Nucl Med 2016; 57: 517-523.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage